California Institute for Quantitative Biosciences

Lisata Therapeutics’ Director and Scientific Founder of the CendR Platform™ Technology, Erkki Ruoslahti, M.D., Ph.D., Receives 2022 Albert Lasker Basic Medical Research Award

Retrieved on: 
Thursday, September 29, 2022

The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.

Key Points: 
  • The Albert Lasker Basic Medical Research Award is one of the highly competitive and distinguished international prizes for medical science awarded by the Lasker Foundation.
  • Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics.
  • Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively.
  • In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

Reliance New Energy Limited to invest in Caelux Corporation

Retrieved on: 
Friday, September 23, 2022

MUMBAI, India, Sept. 23, 2022 /PRNewswire/ -- Reliance New Energy Limited ("RNEL"), a wholly owned subsidiary of Reliance Industries Ltd ("Reliance"), has today signed definitive agreements to invest in Caelux Corporation ("Caelux"), a company headquartered in Pasadena, California, in the United States of America, engaged in the development of perovskite-based solar technology. RNEL will invest USD 12 million to acquire 20% stake in Caelux.

Key Points: 
  • MUMBAI, India, Sept. 23, 2022 /PRNewswire/ -- Reliance New Energy Limited ("RNEL"), a wholly owned subsidiary of Reliance Industries Ltd ("Reliance"), has today signed definitive agreements to invest in Caelux Corporation ("Caelux"), a company headquartered in Pasadena, California, in the United States of America, engaged in the development of perovskite-based solar technology.
  • RNEL will invest USD 12 million to acquire 20% stake in Caelux.
  • RNEL and Caelux have also entered into a strategic partnership agreement for technical collaboration and commercialization of Caelux's technology.
  • Through this investment and collaboration, Reliance will be able to produce more powerful and lower cost solar modules leveraging Caelux's products.

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

Retrieved on: 
Tuesday, September 13, 2022

Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access.
  • View the full release here: https://www.businesswire.com/news/home/20220913005446/en/
    Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access (Photo: Business Wire)
    Veracyte is deeply committed to pulmonology where we believe there are significant unmet needs in lung cancer and other respiratory diseases that our tests can uniquely address, said Dr. Nova.
  • Dr. Leite joined Veracyte from Intervenn, a private-stage diagnostics company where he was chief business officer, responsible for the companys commercial, partnership and market access strategy.
  • Veracyte, the Veracyte logo, Percepta and Envisia are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.

Where Computation and Experimentation Collide

Retrieved on: 
Wednesday, September 7, 2022

SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- In order for our hearts to form correctly and keep us thriving, hundreds of genes must act together in complex networks. If part of a network malfunctions, cardiovascular disease may arise.

Key Points: 
  • Now, after 5 years as a resident in pediatric genetics at Boston Children's Hospital, Theodoris has returned to San Francisco.
  • In addition to her new role at Gladstone, she is also joining UCSF as an assistant professor in the Department of Pediatrics.
  • Drugs that treat disease by targeting individual dysfunctional genes already exist for many illnesses, especially different types of cancer.
  • This union of computation and experimentation surfaced a promising drug candidate that successfully prevented calcific aortic valve disease in mice.

Arkose Labs Ranks in Top 500 of Inc. 5000 for Second Consecutive Year, Achieving Three-year Revenue Growth Rate of 1,479.57%

Retrieved on: 
Tuesday, August 16, 2022

SAN MATEO, Calif., Aug. 16, 2022 /PRNewswire/ -- Arkose Labs, the global leader in fraud deterrence and account security, announced today that it made the Inc. 5000 2022 list for a second consecutive year with a revenue growth rate of 1,479.57 percent. The Inc. 5000 list is the most prestigious ranking of the fastest-growing private companies in America and represents a one-of-a-kind look at the most successful companies within the economy's most dynamic segment—its independent businesses. Facebook, Chobani, UnderArmour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.

Key Points: 
  • Facebook, Chobani, UnderArmour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.
  • Among the top 500, of which Arkose Labs is one, the average median three-year revenue growth rate soared to 2,144 percent.
  • "Every day I'm meeting with and listening to our customers and prospective customers," said Arkose Labs Chief Revenue Officer Richard Dufty .
  • Companies on the 2022 Inc. 5000 are ranked according to percentage revenue growth from2018 to 2021.

Frazier Healthcare Partners Announces Amy DuRoss as Senior Advisor

Retrieved on: 
Monday, August 1, 2022

Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amy DuRoss has joined the firms Growth Buyout team as a Senior Advisor.

Key Points: 
  • Frazier Healthcare Partners, a leading private equity and venture capital firm focused exclusively on the healthcare industry, is pleased to announce that Amy DuRoss has joined the firms Growth Buyout team as a Senior Advisor.
  • Amy is a great fit with our firms culture, and we are fortunate to have her as a Senior Advisor.
  • Founded in 1991, Frazier Healthcare Partners is a leading private equity firm focused exclusively on the healthcare sector.
  • For more information about Frazier Healthcare Partners, visit www.frazierhealthcare.com .

Global Smart Pills Market Report 2022-2027: Development of Addressable Transmitters Operated as Magnetic Spins Showing High Potential

Retrieved on: 
Tuesday, July 26, 2022

DUBLIN, July 26, 2022 /PRNewswire/ -- The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 26, 2022 /PRNewswire/ -- The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The smart pills market consists of the sales of capsule-sized ingestible medical devices with small embedded electronic products such as sensors, cameras, patches, and trackers.
  • The high cost of smart pills associated with technological advancement will act as a restraint to the market growth.
  • Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills.

Global Smart Pills Market Report 2022-2027: Growing Preference for Non-Invasive Procedures Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022

The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Smart Pills Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The growing preference for non-invasive procedures is driving the smart pills market.
  • Therefore, non-invasive procedures are driving the smart pills market during the period.
  • The high cost of smart pills associated with technological advancement will act as a restraint to the market growth.

Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic Innovations for Neuropsychiatric Health

Retrieved on: 
Wednesday, July 13, 2022

LOS ANGELES and BOSTON, July 13, 2022 /PRNewswire/ -- Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like anxiety, depression and stress response. The program builds on the work of Axial co-founder and Board Member and Seed Health Board Member Dr. Sarkis Mazmanian, whose California Institute of Technology (Caltech) lab first discovered the critical contributions of intestinal microbes and microbial metabolites in neuropsychiatric conditions. With joint expertise across discovery, mechanistic validation, microbial fermentation, scale-up, clinical research and commercialization, the program is uniquely positioned to transform the current paradigm of treatment in mental health.

Key Points: 
  • Dr. Mazmanian's lab was the first to discover that molecular signals from gut bacteria can profoundly influence anxiety behavior.
  • The collaboration between Seed Health and Axial Therapeutics will translate this breakthrough research into novel probiotics and living medicines for a range of cognitive and neuropsychiatric outcomes."
  • Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders.

Seed Health Launches Gut-Brain Development Program with Axial Therapeutics To Translate Caltech Research into Probiotic Innovations for Neuropsychiatric Health

Retrieved on: 
Wednesday, July 13, 2022

LOS ANGELES and BOSTON, July 13, 2022 /PRNewswire/ -- Seed Health, a microbiome science company, and Axial Therapeutics, a clinical-stage biopharmaceutical company, today announced a joint development program targeting the microbiome-gut-brain axis for mental health, with the potential to impact well-being in areas like anxiety, depression and stress response. The program builds on the work of Axial co-founder and Board Member and Seed Health Board Member Dr. Sarkis Mazmanian, whose California Institute of Technology (Caltech) lab first discovered the critical contributions of intestinal microbes and microbial metabolites in neuropsychiatric conditions. With joint expertise across discovery, mechanistic validation, microbial fermentation, scale-up, clinical research and commercialization, the program is uniquely positioned to transform the current paradigm of treatment in mental health.

Key Points: 
  • Dr. Mazmanian's lab was the first to discover that molecular signals from gut bacteria can profoundly influence anxiety behavior.
  • The collaboration between Seed Health and Axial Therapeutics will translate this breakthrough research into novel probiotics and living medicines for a range of cognitive and neuropsychiatric outcomes."
  • Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders.